
Opinion|Videos|February 23, 2024
Patient Case Presentation: A 34-Year-Old Woman with HER+ mBC and Brain Metastases
Rani Bansal, MD, discusses the case of a 54-year-old post-menopausal patient who develops liver and brain metastases after undergoing prior therapy with trastuzumab/pertuzumab and T-DM1.
Advertisement
Episodes in this series

Advertisement
Related to this article

Five-year AI adherence was tied to more hypertension, dyslipidemia, and diabetes in HR+ breast cancer, yet adherence also lowered all-cause mortality.

The FDA approved giredestrant plus everolimus for ER-positive, HER2-negative, ESR1-mutated breast cancer based on data from the phase 3 evERA trial.

The FDA has approved pertuzumab-qcay, a biosimilar of the reference product Perjeta, in HER2-positive breast cancer, based on a data package that showed no meaningful differences in quality, safety, efficacy, or immunogenicity.

Model data suggest anthracycline-based chemotherapy may cost breast cancer survivors a median of 9.4 life-years through biological age acceleration.
Advertisement
Advertisement
Trending on CancerNetwork
1
How Should CAR T and Bispecifics Be Sequenced in Multiple Myeloma?
2
Why CAR T May Belong Before Bispecifics in Multiple Myeloma
3
SNO 2026 Shows Lasting Responses, Ongoing Research for Safusidenib
4
CELMoDs vs T-Cell-Redirecting Therapies at First Relapse in Relapsed/Refractory Multiple Myeloma
5






